CTLA4 p.Pro137Leu
c.410C>T · rs1553657429 · VCV432079
ClinGen expert panel — Antibody Deficiencies VCEP
Likely Pathogenic for autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency. Applied ACMG criteria (verbatim):
PS4 PM1
Curation rationale (ClinGen, verbatim)
NM_005214.5(CTLA4):c.410C>T (p.Pro137Leu) is a missense variant encoding substitution of proline with leucine at amino acid 137. This variant is located within the MYPPPY functional domain (residues 134-139), which is required for interaction with CD80 and CD86 (PM1, PMID: 31396201). Another missense variant in the same codon, NM_005214.5(CTLA4):c.410C>G (p.Pro137Arg), has been classified as likely pathogenic for autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency by the ClinGen Antibody Deficiencies VCEP (PMID: 27102614). Splicing prediction using SpliceAI did not strongly predict an effect on splicing due to either of these variants, however, the comparison variant has a higher Grantham score (103) than the variant under investigation (98), so PM5 is not met. This variant is present in gnomAD v4.1.0 at a total allele frequency of 0.0000006195, with 1 allele / 1,614,162 total alleles across all populations of gnomAD, which is higher than the ClinGen Antibody Deficiencies VCEP PM2_Supporting threshold of <0.000000143. This variant has an allele frequency of 0.0000008474, with 1 allele / 1,180,014 total alleles in the European (non-Finnish) population, which is lower than the BS1 threshold of >0.00000111, so no population code is met. This variant has been reported in at least 4 apparently unrelated probands meeting the VCEP standard for phenotypic criteria, with 3 exceeding 10 phenotype points without genotyping that excluded causes in other loci (PMID: 29729943, PMID: 27102614), and 1 reaching 8 phenotype points with exome sequencing-based genotyping that did not identify an alternative basis for disease in the LRBA gene (PMID: 33275711, PS4). Additional reports of this variant in affected patients are available, but some patient phenotypes are not described in detail (PMID: 34111452), and author lists are overlapping so that the cases are not likely to represent distinct individuals (PMID: 30250467, PMID: 27577878, PMID: 39218359, PMID: 34111452). At least 1 proband had a phenotype that included episodes of headache, hearing impairment, and diplopia with enhancing anomaly in the brain parenchyma and progressive brain lesions (1 pt), hemolytic anemia and thrombocytopenia (2 pts), lymphoid hyperplasia and splenomegaly (2 pts), shingles (2 pts), modest hypogammaglobulinemia (2 pt), decreased specific antibody response to vaccination (1), and defective B-cell differentiation (decreased memory B cells), however, PP4 was not applied since the patient was counted under the PS4 code instead (PMID: 33275711). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal dominant autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Antibody Deficiencies VCEP: PM1 and PS4. (VCEP specifications version 2.0.0).
ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.
Computational evidence
| Protein change | ||
| AlphaMissense | 0.6074 | likely pathogenic ✓ concordant with ClinVar |
|---|---|---|
| REVEL | 0.355 | indeterminate |
| SaProt | LLR -10.74 | damaging |
| ⇒ AlphaMissense and SaProt both call this damaging; REVEL makes no call. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 7.7 | GERP 1.5, phastCons 1 |
| Regional constraint | o/e 0.66 | unconstrained · MANE · 2,198 bp · p 3.2e-07 · regional, not allelic |
| Overall | ||
| CADD | 26.0 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- CTLA4
- Protein
- p.Pro137Leu
- Coding
- c.410C>T
- MANE Select
- NM_005214
- dbSNP
- rs1553657429
- Type
- single nucleotide variant
- Location
- chr2:203870886 (GRCh38)
- Gene constraint
- LOEUF 0.211 · pLI 1.00 (gnomAD)
- Structure
- AlphaFold pLDDT 79.67 · 22 PDB
- Residue 137
- a β-strand; the ig-like v-type domain; the 'important for interaction with cd80 and cd86' region
Disease context
autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: Hashimoto thyroiditissystemic lupus erythematosustype 1 diabetes mellitus 12celiac disease, susceptibility to, 3
For Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency (Orphanet):
- Inheritance
- Autosomal dominant
- Onset
- Adolescent, Adult, Childhood
Similar variants
- CTLA4 p.Pro137Arg Likely pathogenic ★★★ same residue
- CTLA4 p.Pro137Gln Conflicting classifications of pathogenicity ★ ⚠ same residue
- CTLA4 p.Pro137= Likely benign ★ same residue
- CTLA4 p.Arg51Ter Pathogenic ★★★ same condition
- CTLA4 p.Arg75Trp Pathogenic ★★★ ⚠ same condition
- CTLA4 p.Asp153Asn Pathogenic ★★★ ⚠ same condition
- CTLA4 p.Cys35Ter Pathogenic ★★★ same condition
- CTLA4 p.Pro136Ala Likely pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/ctla4-p-pro137leu (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown